Eli Lilly, type 2 diabetes
Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks
Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% remaining diabetes-free at 176 weeks.
But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost ...
Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.
HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...
Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...
With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of ...
A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...
So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...
In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...
One area of heightened focus is the fast-growing market for obesity and diabetes drugs like Mounjaro and Ozempic. Eli Lilly and Novo Nordisk are seeking to broaden insurance coverage for such ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback